01 feb: Insideres handel
01 feb: Vilkår for Nykredits og Totalkredits auktioner
01-02-2018 12:02:23

Coloplast delivers solid Q1 interim results and continues to take market share

Relateret indhold
11 jul - 
Onsdagens aktier: Pandora funklede og Mærsk snublede i ..
11 jul - 
Aktier/middag: Mærsk i bølgegang efter intensivering af..
11 jul - 
Aktier/åbning: Mærsk rammer bunden i rødt C25 efter nyt..
Relateret debat
12 jul - 
Det med analytikere.. Sad selv i aktieafdelingen i en a..
12 jul - 
Næ… det er da rigtigt nok, så l&aeli..
12 jul - 
Tillykke til dem med prisen. Dejligt med en form for be..

Coloplast delivered 8% organic revenue growth and an EBIT margin of 31% at constant exchange rates in the first quarter of the 2017/18 financial year. The results were in line with the company’s guidance.

Coloplast delivered 8% organic revenue growth in the first three months of the 2017/18 financial year, while reported growth in Danish kroner was up by 5% to DKK 3,955m. Reported revenue was adversely affected by the depreciation of USD and dollar-related currencies against DKK.

EBIT amounted to DKK 1,207m for a 2% decline in DKK but a 4% increase at constant exchange rates. The EBIT margin at constant exchange rates was 31% against 33% in the same period last year. In DKK, the EBIT margin was 31%, against 33% last year.

Organic growth rates by business area: Ostomy Care 9%, Continence Care 10%, Urology Care 11%, and Wound & Skin Care negative at 5%. Organic growth, particularly in the wound care business, was adversely affected by price reforms in Greece.

Looking at sales by geographies, the European markets contributed with 4% growth, Other developed markets delivered 18% revenue growth, while Emerging Markets provided a 10% increase.

  • “We’re delivering a solid result for the first quarter, and we are off to a good start to the financial year. We’re performing well in many of our major markets and are generally delivering strong results in Ostomy Care, Continence Care and Urology Care. As an example, we’re delivering double-digit growth, and we see continued increased momentum in the US market,” says Coloplast CEO Lars Rasmussen. 

Coloplast invests in growth

Coloplast invested in sales and marketing initiatives across multiple markets and business areas during the first quarter as part of its ambition to drive organic growth.

In addition, Coloplast is adding a new product to its ostomy care portfolio with the launch of SenSura® Mio Concave, the first ostomy care product designed specifically for people with hernias or curves. 

  • “We’re proud to be able to offer our users the best products in the market, and I’m confident that this new product will make a big difference to our users while giving Coloplast a strong competitive edge. Our ambition is to continue to win market share, and to do that we need innovative products like SenSura® Mio Concave,” says Mr Rasmussen.

In November 2017, Coloplast presented its new long-term financial guidance for the period to 2020. Consistent with its ambition of pursuing non-organic growth opportunities, Coloplast completed the acquisition of French direct-to-consumer home delivery company SAS Lilial in January 2018.

The transaction will strengthen Coloplast’s position and its product and service offering in France and will open for further access to payers.

Financial guidance for 2017/18

Coloplast continues to expect organic revenue growth of ~7% at constant exchange rates. Guidance for reported growth in DKK is lowered by 1pp to 5%–6% due to developments in the USD/DKK exchange rate. The guidance includes a negative effect of DKK 100m due to the patent expiry of SpeediCath® standard catheters and the effects of a comprehensive healthcare reform in Greece of DKK 100m.

Coloplast continues to expect an EBIT margin of 31%-32% at constant exchange rates and a reported EBIT margin of ~31% in DKK.

CONTACTS

Lina Danstrup

Senior Media Relations Manager, Corporate Communications

+45 49 11 26 07

dklina@coloplast.com

 

Ellen Bjurgert

Director, Investor Relations

+45 49 11 33 76

dkebj@coloplast.com

http://prlibrary-eu.nasdaq.com/Resource/Download/a1aa3833-9a58-4b92-9818-83c0b8055408

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
12 jul
COLO-B
Kan se du har skrevet i min tidligere tråd skrev præcist det samme (link i hovedteksten). Siden er a..
2
12 jul
COLO-B
  Jeg skrev i maj (se Tidligere tråd ) at Coloplast måske ville bryde 4 års konsolidering og gå mod ..
2
12 jul
COLO-B
Realisten2: Jeg evaluere dag for dag. Som skrevet ovenfor virker markedet ikke særlig bekymret ved e..
1
12 jul
COLO-B
Arhh pas nu på at vi ikke bliver for sensitive. Der er blevet sagt det der var værre herinde og iøvr..
1
12 jul
COLO-B
Nu er prisdannelsen heldigvis markedets samlede mening og over de seneste måneder virker det til at ..
1
12 jul
COLO-B
Jeg fornemmer en halvsur mavefornemmelse ovre ved dig over årets stigning, men må indrømme at jeg ha..
1
12 jul
COLO-B
Coloplast har været plaget af nogle trælse sager, som såvidt jeg er orienteret, er kommet ud af syst..
1

Topdanmark/ABG: hæver kursmålet til 270 kr. fra 235 kr.

13-07-2018 14:23:25
Topdanmark får hævet sit kursmål til 270 kr. fra 235 kr. hos ABG Sundal Collier. Det fremgår af Bloomberg News.Opjusteringen af kursmålet ændrer ikke ved anbefalingen, som forbliver "sælg".Forsikringsaktien handles fredag 1 pct. højere i 310,20 kr. frem/ritzau/FINANS

Unibrew/CEO: Nøglefokus er nu på de opkøb vi har foretaget

13-07-2018 08:26:36
Om der er flere opkøb i vente fra Royal Unibrew vil topchefen Hans Savonije ikke oplyse, men han vil have fokus på de opkøb, der nu er foretaget senest med opkøbet af franske Etablissements Geyer Fréres for 660 mio. kr. Det siger han til Ritzau Finans. - Om der er flere opkøb i vente vil jeg ikke oplyse, siger han, og tilføjer:- Vi har en masse på vores tallerken nu. Så nu er fokus på, at de akti..

NKT taber ankesag om kartelbøde

12-07-2018 12:27:34
NKT og ti andre kabelproducenter har tabt en ankesag om en samlet kartelbøde på 302 mio. euro (2,25 mia. kr.), de blev idømt i 2014. Det skriver Bloomberg News.EU-Kommissionen kom dengang frem til, at de 11 kabelselskaber havde ageret som et kartel fra 1999 og godt ti år frem. NKT's andel af bøden var dog kun 3,9 mio. euro, svarende til cirka 29 mio. kr., mens Nexans og Prysmian fik de klart størs..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Coloplast B A/S 665,60 -0,7% Fald i aktiekurs
Coloplast 101,75 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
15. juli 2018 21:34:03
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180712.1 - EUROWEB4 - 2018-07-15 21:34:03 - 2018-07-15 21:34:03 - 1 - Website: OKAY